The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
DREAMseq: A phase III trial of treatment sequences in BRAFV600-mutant (m) metastatic melanoma (MM)—Final clinical results.
 
Michael Atkins
Leadership - Werewolf Therapeutics
Stock and Other Ownership Interests - Pyxis; Werewolf Pharma
Consulting or Advisory Role - 23AndMe; Abbvie; Agenus; AstraZeneca; Aveo; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Innovent Biologics; IO Biotech; Jazz Pharmaceuticals; Merck; Novartis; Oncorena; Pfizer; Pliant; Pyxis; Replimune; Sanofi; Simcha Therapeutics; Syncona; Werewolf Pharma
Research Funding - Agenus (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - BMS Canada; BMS Sweden
 
Sandra Lee
No Relationships to Disclose
 
Bartosz Chmielowski
Consulting or Advisory Role - Atreca; Regeneron; SERVIER; SpringWorks Therapeutics; Treeline Biosciences
Research Funding - Adagene (Inst); Advenchen Laboratories (Inst); Ascentage Pharma (Inst); AskGene Pharma (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Georgiamune (Inst); IDEAYA Biosciences (Inst); immatics (Inst); Immunocore (Inst); Infinity Pharmaceuticals (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); Krystal Biotech (Inst); Macrogenics (Inst); Nested Therapeutics (Inst); Pierre Fabre (Inst); PTC Therapeutics (Inst); RAPT Therapeutics (Inst); Regeneron (Inst); Replimune (Inst); TriSalus Life Sciences (Inst); Xencor (Inst); Xilio Therapeutics (Inst)
Travel, Accommodations, Expenses - immatics
 
Ahmad Tarhini
Consulting or Advisory Role - AstraZeneca; Bayer; BioNTech; Bristol-Myers Squibb; Clinigen Group; ConcertAI; Eisai; Genentech/Roche; Instil Bio; Merck; Nested; Novartis; Partner Therapeutics; Sanofi/Regeneron
Research Funding - Acrotech Biopharma (Inst); Agenus (Inst); Agenus (Inst); Bristol-Myers Squibb (Inst); Clinigen Group (Inst); Genentech/Roche (Inst); InflaRx (Inst); Merck (Inst); OncoSec (Inst); Pfizer (Inst); Sanofi/Regeneron (Inst); Scholar Rock (Inst)
 
Gary Cohen
No Relationships to Disclose
 
Geoffrey Gibney
Consulting or Advisory Role - Bristol-Myers Squibb; HUYA Bioscience International; Immunocore; Iovance Biotherapeutics; Lyell Immunopharma; Merck; Novartis; Pfizer; Regeneron; Replimune
Speakers' Bureau - Immunocore
Research Funding - Exelixis (Inst)
 
Thach-Giao Truong
Consulting or Advisory Role - Iovance Biotherapeutics; Merck; Novartis; Pfizer
Research Funding - Amgen (Inst); Bristol-Myers Squibb/Celgene (Inst); Castle Biosciences (Inst); Erasca, Inc (Inst); IDEAYA Biosciences (Inst); immatics (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Novartis; Perspective Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst)
 
Diwakar Davar
Stock and Other Ownership Interests - mBiomics; Zola
Honoraria - ACM Biolabs; Arcus Biosciences; Ascendis Pharma; Castle Biosciences; Clinical Care Options (CCO); Gerson Lehrman Group; GlaxoSmithKline; Immunocore; Medical Learning Group; Merck; Regeneron; Replimune; TriSalus Life Sciences; Xilio Therapeutics
Consulting or Advisory Role - ACM Bio; Ascendis Pharma; Clinical Care Options; Gerson Lehrman Group; Replimune; TriSalus Life Sciences; Xilio Therapeutics
Speakers' Bureau - Castle Biosciences
Research Funding - Arcus Biosciences; CellSight Technologies; Checkmate Pharmaceuticals; GlaxoSmithKline; Merck; Merck; Zucero Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Application No.: 63/124,231; Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy
 
Joe Stephenson
No Relationships to Disclose
 
Brendan Curti
Honoraria - Asante Health; St Joseph Hospital
Consulting or Advisory Role - Merck; Werewolf Therapeutics
Research Funding - Ankyra Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Biomarkers for OX40 response (Inst)
Travel, Accommodations, Expenses - Asante Health; St Joseph Hospital
 
Joanna Brell
No Relationships to Disclose
 
Kari Kendra
Research Funding - GlaxoSmithKline (Inst); Immunocore (Inst); Merck (Inst); National Institute on Aging (Inst); The Melanoma Research Foundation (Inst); Varian Medical Systems (Inst)
 
Alexandra Ikeguchi
Research Funding - BioNTech SE (Inst); Immunocore (Inst); Merck (Inst); Regeneron (Inst)
 
Zihe Song
No Relationships to Disclose
 
Samantha Guild
No Relationships to Disclose
 
Jedd Wolchok
Leadership - Ludwig Institute for Cancer Research
Stock and Other Ownership Interests - Apricity Therapeutics; Ascentage Pharma; CellCarta; Georgiamune; Imvaq Therapeutics; Larkspur; Linnaeus Therapeutics; Maverick Therapeutics; Tizona Therapeutics, Inc.; XenImmune Therapeutics
Consulting or Advisory Role - Amgen; Apricity Therapeutics; Ascentage Pharma; AstraZeneca; BeiGene; Bicara Therapeutics; Bristol-Myers Squibb; CellCarta; Chugai Pharma; Daiichi Sankyo,Inc; Dragonfly Therapeutics; Georgiamune; Idera; Immunocore; Imvaq Therapeutics; Larkspur; Maverick Therapeutics; PsiOxus Therapeutics; Recepta Biopharma; Scancell Ltd.; Sellas Life Sciences; Surface Oncology; Takeda; Tizona Therapeutics, Inc.; Trishula Therapeutics; Truvax; Werewolf Therapeutics; XenImmune Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Sephora (Inst)
Patents, Royalties, Other Intellectual Property - ALPHAVIRUS REPLICON PARTICLES EXPRESSING TRP2 (Inst); Anti-GITR antibodies and methods of use thereof (Inst); Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof (Inst); Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof CTLA 4 (Inst); ANTIGEN-RECOGNIZING RECEPTORS TARGETING B7-H3 AND USES THEREOF (Inst); CD40 BINDING MOLECULES AND USES THEREOF (Inst); CD40 binding Molecules and uses thereof (Inst); Engineered Vaccinia Viruses for Cancer Immunotherapy (Inst); I am a co-inventor and receive royalties for a blood test for monitoring myeloid derived suppressor cells. (Inst); I am a co-inventor on a patent for Anti-CD40 agonist mAb fused to Monophosphoryl Lipid A (MPL) for cancer therapy (Inst); I am a co-inventor on a patent for CAR+ T cells targeting differentiation antigens as means to treat cancer (Inst); I am a co-inventor on a patent for use of oncolytic Newcastle Disease virus. (Inst); I am a co-inventor on an issued patent for DNA vaccines for treatment of cancer in companion animals. (Inst); I am co-inventor and receive royalties for a patent for immune modulating antibodies. (Inst); Immunosuppressive follicular helper-like T cells modulated by immune checkpoint blockade (Inst); Peripheral Blood Phenotype Linked to Outcomes After Immunotherapy Treatment (Inst); Phosphatidylserine Targeting Agents and uses thereof for adoptive T-cell therapies (Inst); RECOMBINANT POXVIRUSES FOR CANCER IMMUNOTHERAPY (Inst); WITH IMMUNOMODULATORY THERAPEUTICS AND METHOD OF MONITORING ABSCOPAL EFFECTS DURING SUCH TREATMENT (Inst)
Other Relationship - Immunocore
 
Antoni Ribas
Leadership - Arcus Biosciences; Lutris
Stock and Other Ownership Interests - 4c Biomed; Advaxis; Appia Bio; Arcus Biosciences; Compugen; CytomX Therapeutics; Highlight Therapeutics; ImaginAb; ImmPACT-Bio; Inspirna; Kite/Gilead; Lutris; MapKure; Merus; Pluto Immunotherapeutics; Sastra; Synthekine; Tango Therapeutics; Vial
Honoraria - Amgen; AstraZeneca; Chugai/Roche; Genentech/Roche; Merck Sharp & Dohme; Novartis; Sanofi; Vedanta Biosciences
Consulting or Advisory Role - Amgen; Chugai Pharma; Merck; Novartis; Sanofi
Research Funding - Agilent (Inst); Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Non-viral gene editing to Arsenal Bio
 
John Kirkwood
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Ankyra Therapeutics; AXIO Research; Boxer Capital; Bristol Myers Squibb; CytomX Therapeutics; DermTech; Engage Health Media; iOnctura; Iovance Biotherapeutics; IQVIA; Istari Oncology; Jazz Pharmaceuticals; Lumira Capital Investment Management; Lytix Biopharma; Magnolia Innovation; Merck; Mural Oncology; Natera; Novartis; OncoCyte; PATHAI; Pfizer; Piper Sandler; PyrOjas Corporation; Regeneron; Replimune; Scopus BioPharma; Takeda; Valar Labs; Zola Therapeutics
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Harbour BioMed (Inst); Immunocore (Inst); Immvira (Inst); Iovance Biotherapeutics (Inst); Lion Biotechnologies (Inst); Lytix Biopharma (Inst); Novartis (Inst); Takeda (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Ankyra Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Iovance Biotherapeutics; Regeneron